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sheds light on this clinically relevant population.
What exactly is oligometastatic disease in patients with prostate cancer? There has not yet been a consensus definition, and this highlights the difficult nature of this disease state. Some studies have considered patients with one to three metastases as having oligometastatic disease, 2 whereas
other studies have an expanded definition allowing one to five lesions. 3 Current studies have tried to stratify disease as high volume versus low volume to tease out subgroups of patients with hormone-sensitive metastatic prostate cancer that would benefit from more aggressive therapy. 4 Clinical outcomes and data show that patients with limited metastatic disease often do better than patients with high-volume metastases, regardless of treatment modality. 5 This clinical phenomenon may account for the larger benefit of the chemohormonal therapy of androgen deprivation and docetaxel in highvolume disease but lack of a benefit in patients with low-volume disease. 4 Prospective data are limited with regard to treatment of recurrent nodal disease and directed treatment of distant oligometastatic sites, but some small series have shown biochemical control, notable periods of cancer-specific survival, and delay in androgen deprivation with salvage lymphadenectomy. 9 Stereotactic body radiotherapy (SBRT) has also been used in a small series of patients presenting with up to three bone metastases or lymph nodes. Androgen deprivation in these patients was delayed a median of 38 months, potentially sparing the adverse effects of castration. 10 A few retrospective analyses show increased progression-free survival with focused SBRT to metastases, and several prospective studies are ongoing for limited bone disease treated by SBRT. The choice of imaging and appropriate end point in these studies will be important given future systemic therapies that may affect an overall survival end point. In summary, when patients present with oligometastatic or potentially curative M1 disease, it is necessary to use available data to develop a treatment plan that correlates with the goal for each patient, especially when considering non-standardof-care, local definitive therapy in the setting of metastatic disease. Participation in clinical trials pertinent to these patients should be encouraged. Moreover, care within multidisciplinary clinics and tumor boards is vital to optimize outcomes. Whereas patients with any amount of metastatic disease traditionally only receive androgen deprivation, an exciting new frontier of enhanced imaging techniques, surgical and radiotherapeutic options, and more aggressive first-line systemic therapies suggests that we may be able to do better for our patients with oligometastatic disease. The review presented by Clement and Sweeney 1 highlights many of the key points to consider in our practices and reminds us of the challenges to attaining optimal outcomes.
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